Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER vs DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Peritoneal dialysis solution; dextrose provides osmotic gradient for ultrafiltration and solute removal; low magnesium formulation reduces magnesium accumulation in renal failure patients.
Delflex with Dextrose 3.5% is a peritoneal dialysis solution that uses a high concentration of dextrose to create an osmotic gradient, drawing water and solutes from the blood across the peritoneal membrane into the dialysate, thereby removing excess fluid and waste products from the body. Dextrose is metabolized locally and systemically.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day; dextrose concentration and fill volume adjusted based on ultrafiltration needs.
Intraperitoneal administration: 2000 mL per exchange, typically 4 exchanges per day, with dwell times of 4-6 hours (CAPD) or cycler-adjusted for APD.
None Documented
None Documented
Terminal elimination half-life not applicable; drug effects persist as long as solution remains in peritoneal cavity (dwell time 4–8 hours for CAPD).
3-5 hours (prolonged in renal impairment; anuria up to 24-36 hours)
Renal: 99% (as glucose and electrolytes), biliary/fecal: <1%
Renal: >90% unchanged drug; biliary/fecal: minimal (<5%)
Category C
Category C
Peritoneal dialysis solution
Peritoneal dialysis solution